http://orcid.org/0000-0001-9402-7404
References
- Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, et al. Do we need to adjudicate major clinical events? Clin Trials. 2008;5:56–60.
- Sepehrvand N, Zheng Y, Armstrong PW, Welsh R, Goodman SG, Tymchak W, et al. Alignment of site versus adjudication committee-based diagnosis with patient outcomes: insights from the providing rapid out of hospital acute cardiovascular treatment 3 trial. Clin Trials. 2016;13:140–8.
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736–47.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.
- Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol. 2018;71:1021–34.
- Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Eur Heart J. 2018;39:2192–207.
- Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001;2:187–94.
- Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014;63:1493–9.
- Kosmidou I, Mintz GS, Jatene T, Embacher M, Redfors B, Wong SC, et al. Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: Insights from the HORIZONS-AMI trial. EuroIntervention 2018;14:e580–7.
- Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587–97.
- Frobert O, Lagerqvist B, Gudnason T, Thuesen L, Svensson R, Olivecrona GK, et al. Thrombus aspiration in ST-elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale. Am Heart J. 2010;160:1042–8.
- Erlinge D, Koul S, Eriksson P, Scherstén F, Omerovic E, Linder R, et al. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction–a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). Am Heart J. 2016;175:36–46.
- James S, Frobert O, Lagerqvist B. Cardiovascular registries: a novel platform for randomised clinical trials. Heart. 2012;98:1329–31.
- Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, et al. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med. 2017;376:1813–23.
- Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377:1132–42.
- Kjoller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, et al. Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial. Am Heart J. 2014;168:197–204. e1–4.